Humacyte (HUMA) Q3 2024 earnings summary

Executive summary

• FDA review of the BLA for HAV/ATEV in vascular trauma is ongoing with no new timeline; commercial preparations and confidence in approval continue.

• Positive top-line and subgroup results from the VO7/V007 Phase III trial in hemodialysis access were presented, showing superior function and patency, especially in high-need and underserved subgroups.

• Patent protection expanded for the BioVascular Pancreas (BVP) product candidate for type 1 diabetes, with promising preclinical results.

• Long-term humanitarian use in Ukraine demonstrated high patency and limb salvage in severe vascular trauma cases.

• The company has not generated product revenue to date and faces substantial doubt about its ability to continue as a going concern without FDA approval or additional capital.

Financial highlights

• No revenue reported for Q3 2024 or the nine months ended September 30, 2024.

• Q3 2024 R&D expenses were $22.9M, up from $18.6M in Q3 2023, but down from $23.8M in Q2 2024.

• General and administrative expenses rose to $7.3M in Q3 2024 from $6.1M in Q3 2023, reflecting increased sales and marketing costs.

• Net loss for Q3 2024 was $39.2M, compared to $26.0M in Q3 2023 and $56.7M in Q2 2024.

• Cash, cash equivalents, and restricted cash totaled $71.0M as of September 30, 2024, with an additional $29.6M raised post-quarter.

Outlook and guidance

• Confident in HAV/ATEV approval for vascular trauma and preparing for commercialization.

• Additional capital will be required within the next year to fund operations, with future funding needs dependent on regulatory outcomes and commercialization.

• Supplemental BLA for AV access may be filed in mid-2025, pending FDA feedback on required follow-up duration.

• PAD phase III trial design is ready but will require improved cash position or partnership to initiate.

• NTAP application submitted to CMS for HAV/ATEV reimbursement, targeting FY2026 cycle.